BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31780656)

  • 41. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
    Kaczmar J; Mehra R
    Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting anaplastic lymphoma kinase in neuroblastoma.
    Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
    APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
    Goyal S; Jamal S; Shanker A; Grover A
    J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
    Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
    Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
    Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
    De Pas T; Pala L; Catania C; Conforti F
    Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
    Mehlman C; Chaabane N; Lacave R; Kerrou K; Ruppert AM; Cadranel J; Fallet V
    J Thorac Oncol; 2019 May; 14(5):e95-e96. PubMed ID: 31027750
    [No Abstract]   [Full Text] [Related]  

  • 51. Role and targeting of anaplastic lymphoma kinase in cancer.
    Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
    Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
    Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
    Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
    Diaz-Jimenez A; Ramos M; Helm B; Chocarro S; Frey DL; Agrawal S; Somogyi K; Klingmüller U; Lu J; Sotillo R
    Drug Resist Updat; 2024 May; 74():101081. PubMed ID: 38521003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
    Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
    Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.
    Yu Z; Zhao R
    Anticancer Drugs; 2018 Jul; 29(6):513-519. PubMed ID: 29570100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.